Core Viewpoint - Contango ORE, Inc. (CTGO) shows significant potential for upside, with a current trading price of $21.30 and a mean price target of $29.33, indicating a 37.7% upside potential [1] Price Targets and Analyst Consensus - The average price target for CTGO ranges from a low of $26.00 to a high of $32.00, with a standard deviation of $3.06, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates a potential increase of 22.1%, while the highest suggests a 50.2% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about CTGO's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - The Zacks Consensus Estimate for the current year has increased by 176.9% over the past month, with one estimate rising and no negative revisions [12] - CTGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the magnitude of potential gains, it does provide a useful guide for the direction of price movement [14]

Group 1 - The stock of Kemper (KMPR) closed at $63.29, showing a 1.3% gain over the past four weeks, with a mean price target of $82.2 indicating a potential upside of 29.9% [1] - The average price targets from analysts range from a low of $75.00 to a high of $90.00, with a standard deviation of $5.72, suggesting a variability in estimates; the lowest estimate indicates an 18.5% increase, while the highest points to a 42.2% upside [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.2% over the past month, with one estimate going higher and no negative revisions [12] - Kemper currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, the implied direction of price movement appears to be a good guide [14]

Core Viewpoint - Rapt Therapeutics (RAPT) shares have seen a 1.7% increase over the past four weeks, closing at $7.84, with analysts suggesting a potential upside of 282.7% based on a mean price target of $30 [1] Price Targets and Estimates - The average price target for RAPT ranges from a low of $8.00 to a high of $48.00, with a standard deviation of $21.04, indicating variability in analyst estimates [2] - The lowest estimate suggests a 2% increase from the current price, while the highest estimate indicates a potential upside of 512.2% [2] - Analysts' consensus on price targets is often questioned, as they may not accurately reflect future stock prices [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about RAPT's earnings prospects, with a consensus indicating better-than-previously estimated earnings [4][11] - Over the last 30 days, one earnings estimate has increased, leading to a 22.6% rise in the Zacks Consensus Estimate for the current year [12] - RAPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of RAPT's potential gains, the direction implied by these targets appears to be a useful guide for investors [14]

Core Viewpoint - Avadel (AVDL) shows potential for significant upside, with a mean price target of $17.38 indicating an 81.6% increase from its current price of $9.57 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $3.70, suggesting variability in analyst predictions [2] - The lowest price target of $12 indicates a 25.4% increase, while the highest target of $22 suggests a potential surge of 129.9% [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about AVDL's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, one estimate has increased, leading to a 55% rise in the Zacks Consensus Estimate for the current year [12] - AVDL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Dream Finders Homes Inc. (DFH) has shown a 1.6% increase in stock price over the past four weeks, closing at $23.55, with a potential upside of 25.3% based on Wall Street analysts' mean price target of $29.50 [1] Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $4.44, indicating variability among analysts; the lowest estimate suggests a 10.4% increase to $26, while the highest predicts a 46.5% surge to $34.50 [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about DFH's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 0.9% over the past month, with one estimate increasing and no negative revisions [12] - DFH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]

Core Viewpoint - Byrna Technologies Inc. (BYRN) has seen a 16.8% increase in share price over the past four weeks, closing at $28.79, with a potential upside of 26.8% based on Wall Street analysts' mean price target of $36.50 [1] Group 1: Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $3.12, indicating a range of potential outcomes; the lowest estimate suggests a 14.6% increase to $33, while the highest predicts a 35.5% surge to $39 [2] - Analysts' consensus on earnings estimates has improved, with a positive trend in revisions indicating potential upside for BYRN, as historical data shows a strong correlation between earnings estimate revisions and stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 1.5% due to one upward revision and no negative revisions in the last 30 days, reflecting growing optimism among analysts [12] Group 2: Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can mislead investors; empirical research suggests that price targets rarely indicate actual stock price movements [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research into fundamental drivers [9] - While price targets should not be the sole basis for investment decisions, they can provide useful directional guidance when considered alongside other factors [10][13]

Group 1 - The RealReal (REAL) stock closed at $5.71, showing a 13.1% gain over the past four weeks, with a mean price target of $10.10 indicating a potential upside of 76.9% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $3.09, where the lowest estimate is $7 (22.6% increase) and the highest is $15 (162.7% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 64.3% over the past month, with no negative revisions [12] - REAL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate the direction of price movement [13]

Group 1 - QuinStreet (QNST) shares have increased by 8.1% over the past four weeks, closing at $16.06, with a mean price target of $28.40 indicating a potential upside of 76.8% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $5.90, where the lowest estimate of $19 suggests an 18.3% increase, and the highest estimate of $35 indicates a potential surge of 117.9% [2] - Analysts show a consensus that QNST will report better earnings than previously estimated, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for QNST has increased by 31.4% due to two estimates moving higher and one moving lower over the last 30 days [12] - QNST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets can be misleading, the direction indicated by the consensus price target may serve as a useful guide for potential price movements [10][13]

Group 1 - Silence Therapeutics PLC Sponsored ADR (SLN) shares have increased by 52% in the past four weeks, closing at $5.41, with a mean price target of $35.50 indicating a potential upside of 556.2% [1] - The mean estimate consists of six short-term price targets with a standard deviation of $23.86, where the lowest estimate is $3 (44.6% decline) and the highest is $75 (1286.3% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for SLN has increased by 4.4% due to one upward revision in the last 30 days, with no negative revisions [12] - SLN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it suggests a positive direction for price movement [13]

Core Viewpoint - Agenus (AGEN) shares have increased by 68.4% over the past four weeks, closing at $5, with a mean price target of $6.33 indicating a potential upside of 26.6% [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $2.08, where the lowest estimate of $4 suggests a 20% decline, while the highest target of $8 indicates a potential 60% increase [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, three EPS estimates for the current year have been revised upward, leading to a 52.4% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - Agenus holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]